RecruitingAortic Stenosis
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Eligible age
50–80 yrs
Accepts
All genders
Locations
14 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Sponsor: Novartis Pharmaceuticals
You may qualify if…
- ✓ Male and female ≥50 to \<80 years of age at Screening Part II
- ✓ Lp(a) ≥175 nmol/L at the screening visit, measured at the Central laboratory
- ✓ Mild or moderate calcific aortic valve stenosis
- ✓ At the randomization visit, participant must be optimally treated for existing CV risk factors
You may not qualify if…
- ✕ Severe calcific aortic valve stenosis
- ✕ Uncontrolled hypertension
- ✕ History of malignancy of any organ system
- ✕ History of hemorrhagic stroke or other major bleeding
- ✕ Platelet count ≤ LLN
- ✕ Active liver disease or hepatic dysfunction
- ✕ Significant kidney disease
- ✕ Pregnant or nursing women
Where it's recruiting
Alabama
Huntsville
California
Beverly Hills · Covina · Northridge · Palo Alto …
Florida
Boca Raton · Bradenton · Miami · Miami Lakes …
Kansas
Overland Park
Massachusetts
Boston
Michigan
Detroit · Flint · Royal Oak
Minnesota
Minneapolis
New Jersey
Summit
New York
Albany · New York · Rochester
North Carolina
Winston-Salem
Ohio
Cincinnati · Columbus
Pennsylvania
Philadelphia
Source: ClinicalTrials.gov · NCT05646381 · last updated 2026-06-23